Abstract
Alzheimer’s disease is associated with sleep disorders. Recently, animal studies demonstrated a link between hypocretin, a sleep-regulation neurotransmitter, and AD pathology. In this study, we investigated the circadian rhythm of hypocretin-1 in Alzheimer’s Disease (AD) patients and controls. Moreover, we assessed the relation between CSF hypocretin-1 and amyloid-β. A continuous CSF sampling study via indwelling intrathecal catheter was performed to collect hourly CSF samples of six patients with AD (59-85 yrs, MMSE 16-26) and six healthy volunteers (64-77 yrs). CSF hypocretin-1 and Aβ42 concentrations were determined at 8 individual time points over 24 hours. A circadian pattern was assessed by fitting a 24 hour sine curve to the hypocretin-1 data using mixed model analysis. Clinical diagnosis and Aβ42 were entered into the model as time invariant covariates to determine differences between AD and controls, and correlate Aβ42 to hypocretin-1 levels. A hypocretin-1 circadian rhythm with an amplitude of 11.5 pg/ml was found in clinical AD patients, which did not differ from the control group (7.15 pg/ml). Lower mean CSF Aβ42 levels were related to lower hypocretin-1 levels; 1.6 pg/ml hypocretin-1 per 10 pg/ml Aβ42 (p=0.03), and a higher amplitude of the hypocretin-1 circadian rhythm (0.4 pg/ml, p=0.03). CSF hypocretin-1 has a circadian rhythm for which we could show no difference between AD and controls. However, the association between mean Aβ42 levels and mean hypocretin-1 levels and amplitude may suggest a relationship between AD pathology and hypocretin disturbance, which could hold possibilities for treatment of AD related sleep disorders.
Keywords: Amyloid-β, Cerebrospinal fluid, circadian rhythms, hypocretin, neurobiology, peptides, sleep, sleep disturbances
Current Alzheimer Research
Title:Association between Hypocretin-1 and Amyloid-β42 Cerebrospinal Fluid Levels in Alzheimer’s Disease and Healthy Controls
Volume: 9 Issue: 10
Author(s): Diane Slats, Jurgen A.H.R. Claassen, Gert Jan Lammers, Rene J. Melis, Marcel M. Verbeek and Sebastiaan Overeem
Affiliation:
Keywords: Amyloid-β, Cerebrospinal fluid, circadian rhythms, hypocretin, neurobiology, peptides, sleep, sleep disturbances
Abstract: Alzheimer’s disease is associated with sleep disorders. Recently, animal studies demonstrated a link between hypocretin, a sleep-regulation neurotransmitter, and AD pathology. In this study, we investigated the circadian rhythm of hypocretin-1 in Alzheimer’s Disease (AD) patients and controls. Moreover, we assessed the relation between CSF hypocretin-1 and amyloid-β. A continuous CSF sampling study via indwelling intrathecal catheter was performed to collect hourly CSF samples of six patients with AD (59-85 yrs, MMSE 16-26) and six healthy volunteers (64-77 yrs). CSF hypocretin-1 and Aβ42 concentrations were determined at 8 individual time points over 24 hours. A circadian pattern was assessed by fitting a 24 hour sine curve to the hypocretin-1 data using mixed model analysis. Clinical diagnosis and Aβ42 were entered into the model as time invariant covariates to determine differences between AD and controls, and correlate Aβ42 to hypocretin-1 levels. A hypocretin-1 circadian rhythm with an amplitude of 11.5 pg/ml was found in clinical AD patients, which did not differ from the control group (7.15 pg/ml). Lower mean CSF Aβ42 levels were related to lower hypocretin-1 levels; 1.6 pg/ml hypocretin-1 per 10 pg/ml Aβ42 (p=0.03), and a higher amplitude of the hypocretin-1 circadian rhythm (0.4 pg/ml, p=0.03). CSF hypocretin-1 has a circadian rhythm for which we could show no difference between AD and controls. However, the association between mean Aβ42 levels and mean hypocretin-1 levels and amplitude may suggest a relationship between AD pathology and hypocretin disturbance, which could hold possibilities for treatment of AD related sleep disorders.
Export Options
About this article
Cite this article as:
Slats Diane, A.H.R. Claassen Jurgen, Jan Lammers Gert, J. Melis Rene, M. Verbeek Marcel and Overeem Sebastiaan, Association between Hypocretin-1 and Amyloid-β42 Cerebrospinal Fluid Levels in Alzheimer’s Disease and Healthy Controls, Current Alzheimer Research 2012; 9 (10) . https://dx.doi.org/10.2174/156720512804142840
DOI https://dx.doi.org/10.2174/156720512804142840 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Protective or Damaging Immunity in Infection (Guest Editors: Jose Gutierrez and Antonio Sorlozano)]
Current Immunology Reviews (Discontinued) Acknowledgements to Reviewers:
Neuroscience and Biomedical Engineering (Discontinued) Editorial [Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites (Guest Editor: Milen I. Georgiev)]
Current Medicinal Chemistry Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Current Alzheimer Research Association of DRD2 TaqIA and DβH -1021C>T Gene Polymorphisms with Smoking Initiation and their Interaction with Serotonergic System Gene Polymorphisms
Current Pharmacogenomics and Personalized Medicine Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry Editorial:Advanced Methods of Biomedical Signal Processing for Early Detection of Alzheimer`s Disease
Current Alzheimer Research Role of the Region 23-28 in Aβ Fibril Formation: Insights from Simulations of the Monomers and Dimers of Alzheimers Peptides Aβ40 and Aβ42
Current Alzheimer Research Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders
Current Neuropharmacology Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies
Reviews on Recent Clinical Trials Electromagnetic Fields Act Similarly in Plants as in Animals: Probable Activation of Calcium Channels via Their Voltage Sensor
Current Chemical Biology Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Diseases Associated with General Amino Acid Transporters of the Solute Carrier 6 Family (SLC6)
Current Molecular Pharmacology Maternal Fish Oil Supplementation: The Prodrom of Synaptic Protection in Alzheimers Disease
Current Nutrition & Food Science Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Nanotechnology for Alzheimer Disease
Current Alzheimer Research